BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#131 of 347

Ross Osborn

Cantor Fitzgerald · Equity Research Analyst
EstablishedRating since 2023No new ratings since Jun 2025

Analyst rating accuracy & track record

Ross Osborn is an equity research analyst at Cantor Fitzgerald. Bullish Whales has scored 62 of their stock calls across 15 companies. Their picks beat their sector 34% of the time over the next 12 months, and their price targets were reached 25% of the time within a year.

Win % vs sector
34%
PT Hit % (12mo)
25%
Avg sector-excess
−3.7%
Scored calls
62
Tickers
15
Tier
Established

Track record

Bullish Whales has scored 62 of Ross Osborn's stock calls across 15 companies, dating back to 2023. Their rated stocks beat their own sector 34% of the time over the next 12 months. On a typical call, a Osborn pick returned −3.7% more than its sector over the following year.

Of the scored calls, 62 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
TLSITriSalus Life Sciences Inc.
Buy$9.00Jun 2025−56.1%Miss
TLSITriSalus Life Sciences Inc.
Buy$9.00Jun 2025−56.1%Miss
LUCDLucid Diagnostics Inc
Buy$2.00May 2025−32.3%Miss
XGNExagen Inc
Buy$7.00May 2025−50.4%Hit
SIBNSi-Bone Inc
Buy$25.00May 2025−35.0%Miss
NNOXNano X Imaging Ltd
Buy$9.00Apr 2025−55.1%Miss
LUCDLucid Diagnostics Inc
Buy$2.00Mar 2025−30.0%Miss
SMTISanara Medtech Inc
Buy$46.00Mar 2025−44.6%Miss
ELUTElutia Inc.
Buy$8.00Mar 2025−67.3%Miss
AXGNAxogen Inc
Buy$24.00Mar 2025+59.2%Hit
MDXGMiMedx Group Inc
Buy$13.00Feb 2025−51.2%Miss
SIBNSi-Bone Inc
Buy$25.00Feb 2025−21.6%Miss
CERSCerus Corporation
Buy$4.00Feb 2025+35.8%Miss
SMTISanara Medtech Inc
Buy$44.00Jan 2025−52.5%Miss
PREPrenetics Global Ltd
Buy$9.00Jan 2025+164.8%Hit
XGNExagen Inc
Buy$8.00Jan 2025+57.7%Hit
AVRAnteris Technologies Global Corp. Common Stock
Buy$9.00Jan 2025−27.8%Miss
NNOXNano X Imaging Ltd
Buy$12.00Dec 2024−62.0%Miss
PREPrenetics Global Ltd
Buy$9.00Dec 2024+170.6%Hit
NNOXNano X Imaging Ltd
Buy$11.00Nov 2024−37.3%Hit
LUCDLucid Diagnostics Inc
Buy$2.00Nov 2024+3.8%Miss
ELUTElutia Inc.
Buy$10.00Nov 2024−88.6%Miss
CVRXCVRx Inc
Buy$14.00Oct 2024+0.2%Hit
NNOXNano X Imaging Ltd
Buy$14.00Sep 2024−25.6%Miss
CVRXCVRx Inc
Buy$14.00Sep 2024+7.2%Hit
ELUTElutia Inc.
Buy$10.00Sep 2024−44.7%Miss
PACBPacific Biosciences of California
Buy$3.50Aug 2024−3.4%Miss
ELUTElutia Inc.
Buy$10.00Aug 2024−21.3%Miss
MDXGMiMedx Group Inc
Buy$11.00Aug 2024+22.4%Miss
MDXGMiMedx Group Inc
Buy$11.00Jul 2024−4.7%Miss
ELUTElutia Inc.
Buy$11.00Jun 2024−40.1%Miss
ELUTElutia Inc.
Buy$11.00Jun 2024−41.0%Miss
NNOXNano X Imaging Ltd
Buy$17.00May 2024−28.7%Miss
NNOXNano X Imaging Ltd
Buy$17.00May 2024−32.5%Miss
NNOXNano X Imaging Ltd
Buy$18.00May 2024−34.1%Miss
LUCDLucid Diagnostics Inc
Buy$3.00May 2024+47.4%Miss
SMTISanara Medtech Inc
Buy$44.00May 2024+6.6%Miss
XGNExagen Inc
Buy$7.00May 2024+215.2%Hit
ELUTElutia Inc.
Buy$5.00May 2024−43.1%Hit
CERSCerus Corporation
Buy$4.00May 2024−26.6%Miss
PREPrenetics Global Ltd
Buy$9.00Apr 2024+7.9%Miss
LUCDLucid Diagnostics Inc
Buy$3.00Mar 2024+96.6%Miss
SMTISanara Medtech Inc
Buy$44.00Mar 2024−15.3%Miss
CERSCerus Corporation
Buy$3.00Mar 2024−39.1%Miss
NNOXNano X Imaging Ltd
Buy$18.00Feb 2024−49.1%Miss
NYXHNyxoah
Buy$14.00Feb 2024−14.2%Hit
SMTISanara Medtech Inc
Buy$49.00Feb 2024−10.1%Miss
NNOXNano X Imaging Ltd
Buy$18.00Jan 2024+48.2%Miss
AXGNAxogen Inc
Buy$12.00Jan 2024+106.5%Hit
NNOXNano X Imaging Ltd
Buy$24.00Nov 2023−17.6%Miss
Go to

Ross Osborn: analyst track record FAQ

Is Ross Osborn a good stock analyst?

Yes, by track record. Ross Osborn ranks number 131 of 347 of the analysts Bullish Whales scores, with a BW Score of 39 out of 100. Past results do not guarantee future ones.

What is Ross Osborn's win rate?

Ross Osborn's win rate is 34%. Across 62 scored calls, their rated stocks beat their sector 34% of the time over the next 12 months. On a typical call they returned −3.7% more than the sector.

What stocks and sectors does Ross Osborn cover?

Ross Osborn covers 15 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Ross Osborn's price targets accurate?

Ross Osborn's price targets are reached within 12 months 25% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Ross Osborn's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Ross Osborn rank among Wall Street analysts?

Ross Osborn ranks number 131 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30